RxDoctor Payments Data

Charles Tilley

Physician Assistant · le Mars, IANPI 1467502286

Payments from drug & device makers

$2,863in general payments, 2019–2025

Across 213 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$644
  • Alkermes, Inc.$455
  • Johnson & Johnson$378
  • Otsuka America Pharmaceutical, Inc.$367
  • Neurocrine Biosciences, Inc.$322
  • Teva Pharmaceuticals USA, Inc.$230
  • plus $467 from 9 others

What the payments were for

  • Food & beverage$2,63092%
  • Education$2338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,863 in reported general payments places this provider in the 90th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$40,910
Medicare patients
159
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate128$883,914
Invega SustennaPaliperidone Palmitate177$590,451
Invega TrinzaPaliperidone Palmitate11$116,229
VraylarCariprazine Hcl86$86,482
Risperdal ConstaRisperidone Microspheres80$70,762
Aripiprazole394$49,810
Lurasidone Hcl311$44,918
AristadaAripiprazole Lauroxil12$44,736
TrintellixVortioxetine Hydrobromide46$22,458
Clozapine344$15,492
LatudaLurasidone Hcl11$14,741
Olanzapine300$13,882
Paliperidone ErPaliperidone53$13,728
Divalproex Sodium ErDivalproex Sodium299$12,608
QelbreeViloxazine Hcl21$10,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$322$883,914128 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$378$777,442268 claims
AbbVieVraylar, Fetzima$644$92,32998 claims
Alkermes, Inc.Aristada$455$44,73612 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$30$32,31873 claims
Sunovion Pharmaceuticals Inc.Latuda$55$14,74111 claims
Supernus Pharmaceuticals, Inc.Qelbree$80$10,71821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in le Mars

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →